Skip to main content
OpenTrials
Completed

NCT Number: NCT00195715

Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease

To evaluate the long-term maintenance of response, safety and tolerability of repeated administration of adalimumab in subjects with Crohn's disease who participated in and successfully completed Protocol M02-404 or Protocol M04-691.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Site Ref # / Investigator 1938, Camperdown, New South Wales, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject must have successfully completed either the M02-404 (NCT00077779) or M04-691 (NCT00105300) protocol to be eligible for this study
  • Diagnosis of Crohn's disease
  • Willing and able to give informed consent

Exclusion criteria

  • Diagnosis of ulcerative colitis
  • Women cannot be pregnant or breastfeeding
  • Previous history of listeria infection or untreated tuberculosis
  • Previous history of cancer other than successfully treated skin cancer or carcinoma-in-situ of the cervix

Treatment and study plan

Adalimumab

Biological

Adalimumab 40 mg by subcutaneous injection every other week or every week

Other names: ABT-D2E7, Humira

Primary outcomes

  1. Percentage of Subjects Achieving Clinical Remission

    Time frame: Week 156

    Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of < 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

Secondary outcomes

  1. Percentage of Subjects Achieving Clinical Remission

    Time frame: Week 48

    Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of < 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

  2. Percentage of Subjects Achieving Clinical Remission

    Time frame: Week 108

    Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of < 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

  3. Percentage of Subjects Achieving Clinical Remission

    Time frame: Week 204

    Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of < 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

  4. Percentage of Subjects Achieving Clinical Response 100 (CR-100)

    Time frame: Week 156

    A CR-100 is a decrease from baseline in CDAI score of 100 or more points. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

  5. Percentage of Subjects Achieving Clinical Response 70 (CR-70)

    Time frame: Week 156

    A CR-70 is a decrease from baseline in CDAI score of 70 or more points. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

  6. Percentage of Subjects Achieving Steroid-free Clinical Remission

    Time frame: Week 156

    Steroid-free remission was achieved if the subject stopped taking steroids before the visit and had a Crohn's Disease Activity Index (CDAI) score of <150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

  7. Percentage of Subjects Achieving Steroid-free CR-100

    Time frame: Week 156

    Steroid-free CR-100 was achieved if the subject stopped taking steroids before the visit and had a decrease from baseline in CDAI score of 100 or more points at that visit. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

  8. Percentage of Subjects With Fistula Remission

    Time frame: Week 156

    Fistula remission was defined as the absence of draining fistulas in subjects with fistula present at the preceding study's baseline visit.

  9. Percentage of Subjects With Infection

    Time frame: Up to 262 weeks of adalimumab treatment

  10. Percentage of Subjects With Serious Infection

    Time frame: Up to 262 weeks of adalimumab treatment

    Serious infections are infectious adverse events that meet at least one criterion for a serious adverse event (e.g., death, life threatening event, hospitalization) including tuberculosis (TB), bacterial sepsis, invasive fungal infections (e.g., histoplasmosis), and infections due to other opportunistic pathogens.

  11. Percentage of Subjects With Malignancy

    Time frame: Up to 262 weeks of adalimumab treatment

  12. Percentage of Subjects With Lymphoma

    Time frame: Up to 262 weeks of adalimumab treatment

  13. Percentage of Subjects With Nonmelanoma Skin Cancer

    Time frame: Up to 262 weeks of adalimumab treatment

  14. Percentage of Subjects With Malignancy (Excluding Nonmelanoma Skin Cancer and Lymphoma)

    Time frame: Up to 262 weeks of adalimumab treatment

  15. Percentage of Subjects With Malignancy (Including Lymphoma, Excluding Nonmelanoma Skin Cancer)

    Time frame: Up to 262 weeks of adalimumab treatment

  16. Percentage of Subjects With Injection Site Reaction-related Adverse Event

    Time frame: Up to 262 weeks of adalimumab treatment

    An injection site reaction is any adverse event corresponding to a preferred term beginning with "injection site" excluding injection site arthritis, injection site movement impairment, injection site photosensitivity, injection site joint effusion, injection site joint inflammation, injection site scab, injection site joint pain, or injection site laceration.

  17. Percentage of Subjects With Opportunistic Infection (Excluding Tuberculosis)

    Time frame: Up to 262 weeks of adalimumab treatment

  18. Percentage of Subjects With Congestive Heart Failure

    Time frame: Up to 262 weeks of adalimumab treatment

  19. Percentage of Subjects With Demyelinating Disease

    Time frame: Up to 262 weeks of adalimumab treatment

  20. Percentage of Subjects With Hepatic-related Adverse Event

    Time frame: Up to 262 weeks of adalimumab treatment

  21. Percentage of Subjects With Allergic Reaction-related Adverse Event

    Time frame: Up to 262 weeks of adalimumab treatment

  22. Percentage of Subjects With Lupus-like Syndrome

    Time frame: Up to 262 weeks of adalimumab treatment

  23. Percentage of Subjects With Hematologic-related Adverse Event

    Time frame: Up to 262 weeks of adalimumab treatment

  24. Percentage of Subjects With Fatal Adverse Event

    Time frame: Up to 262 weeks of adalimumab treatment

Sponsors and collaborators

Lead sponsor

Abbott

Industry

Registry information

Official study title

A Multi Center, Open Label Study of the Human Anti TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease

Important dates

Study start
2004
Primary completion
2006
Study completion
2008
First posted
Sep 20, 2005
Registry last updated
Jul 12, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.